Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation

Research Council of Norway

Financial schemeJoint transnational calls

ProgramEuropean Rare Disease Research Alliance (ERDERA)

Pre-proposal submission 13 February 2025, 00:00 CET

Full proposal submission9 July 2025, 00:00 CEST

Relevant thematic areas for this callGround-breaking research, Health, Enabling technologies, Democracy and global development

Target groupsPublic sector, Industry, Research organisations

Contact person

Ole Johan BorgeHelse og offentlig sektorojb@forskningsradet.no

The Research Council of Norway is announcing NOK 7 000 000 to Norwegian researchers who want to participate in a European research collaboration on rare diseases.

The Research Council of Norway (RCN) is announcing € 600 000 to Norwegian researchers who wish to contribute to advancing therapeutic solutions for rare diseases. The ERDERA Joint Transnational Call (JTC) 2025 aims to foster international collaboration on interdisciplinary research projects, leveraging complementary expertise to benefit millions of patients worldwide.

Projects should focus on a group of rare diseases or a single rare disease if grouping is not justified, providing a rationale for the latter. Consortia are expected to include and engage patient partners and/or patient advocacy organisations (PAOs).

Projects should address at least two of the following:

Development of novel therapies in a pre-clinical setting.
Creation and validation of predictive and pharmacodynamic biomarkers.
Replication of pre-clinical findings to enhance reliability.
Pre-clinical proof-of-concept studies for therapy readiness.

Please note, certain approaches, including ATMP therapies and clinical trials, are excluded from this call. For guidance about patient’ s involvement please see the call’s website.

Amount of available funding from RCN: € 600 000

Maximum amount of funding per grant: maximum € 300 000 If the Norwegian participant is a partner and maximum € 400.000 if the Norwegian participant has a coordinator role.

Total budget for Norwegian partners in a single project: € 400 000

Amount of total available funding for the call: about 30 million euro

Project duration: 3 years

If the funding recipient is a commercial enterprise, the funding is granted in the form of state aid and is regulated by the state aid rules.

Specialties

Clinical Trials

Public Health

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: Research Council of Norway

Sponsor Type: Corporate/Non-Profit

Address: Postboks 564 1327 Lysaker Visitor address Drammensveien 288 0283 Oslo

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity